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Improving the Utility of Evidence Synthesis for 
Decisionmakers in the Face of Insufficient Evidence  
Structured Abstract  
Background:  Healthcare decision makers strive to operate on the best available evidence. The 
Agency for Healthcare Research and Quality Evidence-based Practice Center (EPC) Program 
aims to support healthcare decision makers by producing evidence reviews that rate the strength 
of evidence. However, the evidence base is often sparse or heterogeneous, or otherwise results in 
a high degree of uncertainty and insufficient evidence ratings.  
 
Objective: To identify and suggest strategies to make insufficient ratings in systematic reviews 
more actionable.  
 
Methods: A workgroup comprising EPC Program members convened throughout 2020. We 
conducted interative discussions considering information from three data sources: a literature 
review for relevant publications and frameworks, a review of a convenience sample of past 
systematic reviews conducted by the EPCs, and an audit of methods used in past EPC technical 
briefs. 
 
Results: Several themes emerged across the literature review, review of systematic reviews, and 
review of technical brief methods. In the purposive sample of 43 systematic reviews, the use of 
the term “insufficient” covered both instances of no evidence and instances of evidence being 
present but insufficient to estimate an effect. The results of the literature review and review of 
the EPC Program systematic reviews illustrated the importance of clearly stating the reasons for 
insufficient evidence. Results of both the literature review and review of systematic reviews 
highlighted the factors decision makers consider when making decisions when evidence of 
benefits or harms is insufficient, such as costs, values, preferences, and equity. We identified five 
strategies for supplementing systematic review findings when evidence on benefit or harms is 
expected to be or found to be insufficient, including: reconsidering eligible study designs, 
summarizing indirect evidence, summarizing contextual and implementation evidence, 
modelling, and incorporating unpublished health system data.  
  
Conclusion: Throughout early scoping, protocol development, review conduct, and review 
presentation, authors should consider five possible strategies to supplement potential insufficient 
findings of benefit or harms. When there is no evidence available for a specific outcome, 
reviewers should use a statement such as “no studies” instead of “insufficient.” The main reasons 
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Introduction  
Systematic reviewers synthesize a body of evidence and rate the strength of evidence 
available for each eligible outcome based on study limitations, consistency, directness, precision, 
and additional factors. When criteria are not adequately met, evidence may be rated as 
“insufficient.” The phrase “insufficient strength of evidence” is used by the Agency for 
Healthcare Research and Quality’s (AHRQ) Evidence-based Practice Center (EPC) Program to 
indicate, “We have no evidence, we are unable to estimate an effect, or we have no confidence in 
the estimate of effect for this outcome. No evidence is available or the body of evidence has 
unacceptable deficiencies, precluding reaching a conclusion.”1 By contrast, the lowest category 
of GRADE certainty of evidence ratings is “very low,” which is defined as, “We have very little 
confidence in the effect estimate [for this outcome]. The true effect is likely to be substantially 
different from the estimate of effect.”2   
The term “insufficient,” may be interpreted differently by various end-users of the review 
and may refer to different limitations of a given literature base. In the absence of qualifiers, 
readers of systematic reviews may conflate the insufficiency of evidence about an effect (e.g., on 
benefits or harms on a particular population, intervention, comparison or outcome) with the 
insufficiency of information to make a decision. Insufficient evidence does not necessarily mean 
that decisionmakers will not or should not act on the evidence that is available. In fact, healthcare 
decision makers consider evidence as one of many decisional factors, which may include patient 
and healthcare provider values and preferences, resources, feasibility, acceptability of the 
recommended actions,3 and concerns about inaction. When there is no evidence or insufficient 
evidence on benefits or harms, information on these other factors may be important to 
summarize for decision makers.4   
A workgroup from the AHRQ EPC Program sought to understand how systematic reviewers 
can support decision making in the face of insufficient evidence. The workgroup aimed to 
identify (1) the various ways in which the term “insufficient evidence” has been used, defined, 
and understood in the literature; (2) published frameworks for decision-making based on 
insufficient evidence; and (3) strategies that can be adopted by systematic reviewers to provide 
additional information to support decision making when facing insufficient evidence. Finally, the 
workgroup provided recommendations for systematic reviewers on how to handle insufficient 





A workgroup comprised members from 9 EPCs (RTI International-University of North 
Carolina, Mayo Clinic, ECRI Institute-Penn Medicine, University of Minnesota/Minneapolis 
VA, Brown University, Kaiser Permanente, Southern California/RAND, Johns Hopkins 
University, University of Connecticut), AHRQ, and the Scientific Resource Center (SRC). We 
met twice monthly for 10 months and gathered additional input from the wider EPC Program at 
two virtual meetings. This report draws on three sources of data: a literature review, a review of 
a purposive sample of EPC reports that identified insufficient evidence, and an audit of EPC 
technical briefs. Technical briefs were reviewed because they are often prepared for topics where 
there is anticipated to be a small body of direct evidence. Technical briefs may answer 
foundational and definitional questions in addition to (or instead of) questions of benefits and 
harms and may use a variety of information sources to guide report writing or support decision 
making. Strategies were subsequently identified and suggested based on the three data sources 
and iterative discussions among the workgroup members.  
Literature Review  
The SRC staff librarian conducted two literature searches (see Appendix A) to identify 
articles describing insufficient evidence in terms of: (1) how it was defined or acted on in 
decision making or guideline development and (2) how different audiences might react to the 
term “insufficient.” The research librarian conducted a first-pass abstract and title screening to 
exclude irrelevant references. The two workgroup leads screened the remaining citations to 
select articles for inclusion. The workgroup members evaluated the included full-text papers for 
relevance and extracted pertinent information into a standardized form. The two workgroup leads 
categorized the articles into five topic areas: (1) types and definitions of insufficient evidence, 
(2) existing frameworks to rate insufficient evidence, (3) decision making in the face of 
insufficient evidence, (4) evidence synthesis and insufficient evidence, and (5) other 
miscellaneous themes. The workgroup organized results thematically and used these findings to 
identify potential recommendations.   
Review of Systematic Reviews 
To uncover how EPCs currently classify and present insufficient evidence ratings, we 
reviewed a purposive sample of systematic reviews previously published by the EPCs. Twelve 
EPCs were asked to select their own examples of at least five examples of systematic reviews, 
either AHRQ funded or non-AHRQ funded, that were completed during the last 5 years, in 
which at least one Key Question had insufficient evidence. Systematic reviews with a specific 
sponsor or stakeholder were prioritized because these reflect scenarios when the review was 
most likely carried out to directly inform decisionmaking.  
For each included review, workgroup members (or a volunteer from the EPC if the EPC was 
not already represented on the workgroup) extracted information pertaining to the decisional 
dilemma addressed by the review, whether the insufficient evidence rating was anticipated at the 
start of the review, reasons for insufficient evidence ratings, any approaches used to address the 
insufficient evidence and help decision makers act on the evidence, and whether the main 
stakeholder of the review made any recommendations based on the insufficient evidence.   
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Audit of Technical Briefs 
Members of the SRC extracted information from 21 technical briefs accepted for publication 
by the AHRQ EPC Program between May 2014 and February 2020. Technical briefs often 
combine multiple sources of information (Key Informant [KI] interviews, published literature, 
grey literature, audits of commercially available products) and they consider practical aspects of 
implementing various clinical or quality improvement interventions.  
Aside from traditional evidence sources, such as systematic reviews and primary literature, 
many briefs also explored sources of data not typically used in systematic reviews, such as 
websites of commercially available products,5-7 clinical practice guidelines,8,9 and numerous 
sources of grey literature(like reports published by state and county health officials).10  
Therefore, we reviewed data sources and analytic approaches that have been used in 
technical briefs. Our review also reported the methods used in technical briefs when the 
questions summarized contextual and implementation information. As a proxy to determine 
whether the intended audience was satisfied with the report and methods used, the SRC 
examined peer and public review comments on the draft technical brief. The SRC also 
considered summaries from the topic nominator to better elucidate the decisional dilemma faced 
by the end-user a priori to commissioning the technical brief. From the technical brief reports, 
peer and public comment summaries, and nomination summaries, the SRC extracted information 
pertaining to the reports’ decisional dilemma, a subjective determination of how well the 
technical brief research questions directly addressed that dilemma, evidence synthesis methods, 
and whether peer and public reviewers recommended substantial changes to the synthesis, 
conduct, or framing of the report. The SRC and EPC workgroup then reviewed the extracted data 
to identify common themes.  
 
Workgroup Discussion and Consensus Process  
The method for determining consensus of these strategies was informal. We discussed issues 






Literature Review  
The initial literature search identified 1,458 articles for review; after title and abstract 
screening 208 references remained. After full-text screening, 73 articles were included in the 
final review. Of these, the workgroup members judged 44 to be relevant. The articles included 
methodology framework papers, systematic reviews, commentaries, opinion pieces, consensus 
documents, and qualitative studies. The reviewed documents are summarized in Appendix B. 
The relevant literature was classified into the following five categories:  
1. Types and definitions of insufficient evidence (n=5): these papers differentiated 
insufficient evidence due to  
a. having no evidence; 
b. imprecision (small number of events and large variance); 
c. other reasons leading to an inability to make a decision despite being able to 
estimate effect size. 
2. Frameworks for rating insufficient evidence (n=2): these papers identified frameworks 
and definitions of insufficient evidence, such the United States Preventive Services Task 
Force (USPSTF) approach.11  
3. Decisionmaking with insufficient evidence (n=27): these papers discussed  
a. challenges of decisionmaking in light of insufficient evidence;  
b. the difficulty of identifying relevant evidence to guide decisions in children, rare 
diseases, and in primary care settings;  
c. patients’ dissatisfaction with uncertainty;  
d. decisionmaking using local health system data (such as data from electronic 
medical records) when the evidence was insufficient;  
e. healthcare providers preference for having a recommendation about management 
even if the evidence was insufficient to support the recommendation.  
4. Evidence synthesis and insufficient evidence (n=1): this paper suggested providing 
additional interpretation and extrapolation by content experts, that was labeled on one 
occasion “rigorous speculation,” to improve evidence uptake when the evidence is 
insufficient.4 
5. Other themes (n=9): these papers discussed 
a. interpretation of p-values; 
b. value of cost effectiveness analysis; 
c. the unique setting of coverage decisions; 
d. making guideline recommendations using GRADE that are strong 
recommendations based on weak evidence.12  
Review of Systematic Reviews  
Nine EPCs analyzed 43 purposefully selected systematic reviews. These reviews are 
summarized in Appendix C. Of these, 29 (67%) were commissioned by the AHRQ EPC 
Program. Other entities that commissioned reviews included international non-for-profit 
organizations (e.g, the World Health Organization), state (e.g., State of Washington) and federal 
entities (e.g, Department of Defense, Veterans Administration), professional societies (e.g, the 
American College of Rheumatology, American Society of Hematology, Endocrine Society, and 
Kidney Disease: Improving Global Outcomes), and academic health systems. The American 
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Academy of Child and Adolescent Psychiatry and the USPSTF were most commonly reported as 
end-users.   
The reviews varied in terms of how the decisional dilemma was phrased. Many statements of 
the decisional dilemma were specific, and included a clear statement of the population, 
intervention, and outcome (e.g., “Should disulfiram be recommended to reduce alcohol use or 
increase abstinence in adolescents with alcohol use disorder?”). A few reported a decisional 
dilemma but phrased it in broader terms (e.g., “To screen or not to screen”).  
Definition of the Term “Insufficient” 
In the 43 systematic reviews, the use of the term “insufficient” covered both instances of no 
evidence (i.e., no studies directly evaluated the population, intervention, or outcome of interest; 
or no studies directly evaluated the research question) and instances of evidence being present 
but insufficient to estimate an effect (or to make a conclusion). Although the reasons for rating 
evidence as insufficient frequently pertained to imprecision and lack of evidence, other reasons 
were high risk of bias in individual studies, and inconsistency among evaluated studies.  
Adding Information Sources to Address the Decisional Dilemma in 
the Context of Insufficient Evidence 
Twenty-six (60%) of the reviews included specific solutions to help address the decisional 
dilemma in the context of insufficient evidence. In 21 (49%) reviews, the finding of insufficient 
evidence was anticipated by the review team (e.g., the systematic review was an update of a 
previous one, or scoping the literature indicated lack of evidence). When authors found 
insufficient evidence for specific outcomes, one set of solutions included summarizing the 
evidence for ineligible populations, interventions (i.e., indirect evidence), and study designs in 
the discussion section of the report. A second solution involved providing information on other 
important factors (not addressed as Key Questions) that may be used to inform decisionmaking; 
these were addressed as contextual questions. A third solution involved revising the review 
criteria to include observational study designs. 
Systematic reviewers offered examples of how they summarized results outside the review 
parameters. For example, a review on screening and early treatment for asymptomatic peripheral 
artery disease with the ankle-brachial index included limited data on screening accuracy in their 
target population (asymptomatic general population).13 To address this, in the discussion section 
of the report, they supplemented the review with a summary of the larger evidence base on 
screening accuracy in populations symptomatic for peripheral arterial disease, recognizing that 
extrapolation may exaggerate the diagnostic accuracy.13 As an example of interventions outside 
the scope of the review, an evaluation of screening for atrial fibrillation with electrocardiograms 
included information on screening with electrocardiograms for atherosclerotic cardiovascular 
disease.14  
Regarding presenting contextual information, several examples came from reviews 
conducted for the USPSTF, which has an established process for summarizing and using 
contextual information for conceptual bounding of benefits and harms.11 For example, this 
process might involve presenting information on incidence of the harm in a narrower population, 
so that the incidence in the general population (with lower risk) can be inferred as very low. 
Other contextual information pertained to the “diagnostic odyssey of the families” for whole 
exome sequencing15 and the “penetrance/prevalence” of multigene panels for hereditary breast 
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cancer risk assessment test.16 Some reviewers described compiling contextual information in a 
rigorous manner (relying on systematic reviews and targeted searches); two specifically 
mentioned clinical judgment and expert opinion.    
Making Recommendations Despite Insufficient Evidence 
Several systematic reviews sponsored by guideline developers described their end-users as 
making recommendations in the context of insufficient evidence. In these instances, contextual 
information supported recommendations for or against the treatment. In a review of whole 
exome sequencing, the end-user “acknowledged the limitations in the evidence, but in the end 
recognized the very specific contextual circumstances regarding use of this test, and felt that 
there was enough of a signal of potential benefit, without significant harms and with some 
evidence of cost-effectiveness that it could be reasonable to use by qualified professionals (i.e. 
medical geneticists) according to specified criteria for use.”15 Another example was a 
recommendation against screening asymptomatic patients with sickle cell disease with 
pulmonary function tests.17 The evidence supporting benefits was deemed insufficient but 
considering the cost and inconvenience of pulmonary function testing, particularly in children, 
the panel made a recommendation against testing. 
Audit of Technical Briefs  
A total of 21 technical briefs were included in this audit. A full listing of the 21 reports 
included in this audit and a summary data abstraction table can be found in Appendix D. Sixteen 
(76%) discussed information from Key Informant (KI) interviews within the findings of their 
report and were not simply being used to assist topic scoping. KI interviews were used to 
summarize contextual or implementation factors and to develop conceptual frameworks or tables 
of theoretical advantages and disadvantages of an intervention. Two technical briefs reported 
using formal qualitative research methodology to analyze content from KI interviews.18,19   
Many technical brief questions focused on practical aspects of decisional dilemmas, such as 
context in which interventions have been studied, implementation strategies for various 
interventions, or barriers and facilitators affecting implementation. Fifteen (71%) included a 
Guiding Question pertaining to contextual or implementation factors. For example, the report 
“Characteristics of Existing Asthma Self-Management Education Packages” interviewed KIs to 
identify practical barriers to effective implementation of chronic asthma self-
management/education packages.6 KIs revealed the need to consider factors well beyond the 
instructional content of these packages, such as patient demographics, health literacy levels, and 
access issues such as the availability of health insurance coverage. Another technical brief that 
assessed the available evidence regarding strategies for comprehensive health management for 
women with HIV/AIDS used input from clinicians and social workers to devise a series of 
clinical vignettes to illustrate complex psychosocial and other contextual issues commonly 
encountered in the care of these patients.20   
Technical briefs also often include analyses of data sources beyond what is typically included 
in systematic reviews. For example, “Pharmacologic and Nonpharmacologic Treatments for 
Posttraumatic Stress Disorder: Groundwork for a Publicly Available Repository of Randomized 
Controlled Trial Data”8 and “Treatment for Acute Pain: An Evidence Map”9 both included 
clinical practice guidelines. “Skin Substitutes for Treating Chronic Wounds,”7 “Characteristics 
of Existing Asthma Self-Management Education Packages,”6 and “Decision Aids for Advance 
Care Planning”21 all abstracted characteristics of commercially available products from industry 
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web pages. The review “Impact of Community Health Worker Certification on Workforce and 
Service Delivery for Asthma and Other Selected Chronic Diseases”10 included reports published 
by State and county health officials on certification requirements posted on state health 
department web pages.  
Data sources for evaluating representativeness of initial decisional dilemma in report scoping 
and subsequent end-user satisfaction were not as readily available as initially anticipated. 
Additional efforts are being taken outside of this workgroup by the SRC and AHRQ to more 
easily link topic nomination decisional dilemma details and feedback with eventual published 
reports. Published disposition of comments tables for technical briefs were the most readily 
available proxy measure, but they should be interpreted cautiously and more as clues for future 
improvements rather than sources to identify problems with past methods.  
Of the 16 technical briefs that included KI information within the findings of their report, 8 
had requests from peer reviewers suggesting samples may not have been representative of all 
relevant stakeholders (6 reports) or all relevant information did not come out of interviews (2 
reports), which could be related to an insufficiently representative sample of KIs. Formal 
qualitative methods rely on representative samples and utilize interview techniques to reach 
thematic saturation. Since technical briefs did not always reach thematic saturation, more formal 
qualitative methods may be useful in providing findings that include the content of importance to 
end-users. Peer reviewers asked for patient advocates or front-line clinicians to be included as 
KIs, and often questioned the selection process for KIs.  
Peer reviewers often asked for an expanded scope of the technical brief to include costs, 




Strategies To Improve Utility of Insufficient Evidence 
The literature review, review of systematic reviews, audit of technical briefs, and iterative 
discussions amongst workgroup members contributed to the development of the following 
strategies that may be used to supplement findings of insufficient evidence. We identified five 
strategies: (1) reconsider eligible study designs, (2) summarize indirect evidence, (3) summarize 
contextual and implementation evidence, (4) consider modelling, and (5) incorporate 
unpublished health system data in the evidence synthesis (e.g., a primary observational study that 
uses data from the electronic medical record of the health system). Table 1 describes these 
strategies with examples. Some of these strategies are consistent with best practices regardless of 
anticipated strength of evidence. When reviewers adopt a strategy, they should follow the 
methodological guidance relevant to the chosen strategy (e.g., best practices of qualitative 
synthesis or modelling) to maintain the rigor and reproducibility.  
 
Table 1. Strategies for addressing insufficient evidence in evidence synthesis programs* 
Strategy Description Example Example Description 
Reconsider eligible study 
designs 
In designing the original 
protocol, authors may 
have anticipated sufficient 
evidence from stronger 
designed studies. 
However, if potential bias 
in design or conduct of the 
study leads to insufficient 
evidence, authors may 
reconsider inclusion of 
observational studies, 
studies without 





The systematic review 
was conducted to support 
a recommendation for or 
against whole exome 
sequencing. The review 
summarized the results 
from single arm studies in 
addition to modeling 
studies and studies with 
comparator arms. 
Summarize evidence 
outside the prespecified 
review parameters 
(indirect evidence) 
Evidence may be sought 
from studies excluded 
during the review process 
due to different 
populations, interventions, 
comparators, and 
settings. These excluded 
studies may have limited 
applicability to the review 
question; use of such 
evidence requires 
appropriate interpretation 
and contextualization by 
clinical experts. These 
results may be 
summarized as contextual 
evidence or in the 
discussion section of the 
report. 
American Society of 
Hematology 2020 
guidelines for sickle cell 
disease: management of 
acute and chronic pain8 
A systematic review was 
done to support guidelines 
about the management of 
pain in individuals with 
sickle cell disease. Due to 
paucity of data, the 
EPCsummarized 
published systematic 
reviews on pain 
management in conditions 
other than sickle cell 
disease that were deemed 
clinically similar by the 
guideline panel. 
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Strategy Description Example Example Description 
Summarize evidence on 
contextual factors (factors 
other than benefits/harms) 
Example 1. 
Decisionmakers must 
consider other factors 
besides evidence on 
effectiveness and harms 
of an intervention. 
Evidence on other factors 
that may affect the 
decision may be helpful to 
decisionmakers, such as 





and safety of cognitive 
behavioral therapy and 
pharmacotherapy for 
childhood anxiety 
disorders: a systematic 




An EPC report about the 
management of anxiety in 
children compared the 
different pharmacological 
and nonpharmacological 
treatments in terms of 
benefits and harms.9 
Additional data were 
summarized in a 
subsequent report10 that 
included contextual and 
implementation 
information (doses of 
common treatments, 
which patients are 
candidate for treatment, 
values and preferences, 
costs and resources, 
acceptability, impact on 
health equity, feasibility, 
alternative therapies, 
remission rates and 
prognosis). Contextual or 
implementation evidence 
may require quantitative 
or qualitative evidence 
synthesis. 
Example 2.  
Studies examining the 
effectiveness of complex 
interventions may be 
challenging to synthesize 
because of heterogeneity 
in interventions or 
populations studied. 
Realist reviews or 
qualitative evidence 
synthesis may be helpful 
to explore reasons for 
heterogeneity, and to 
uncover specific 
conditions under which a 
complex intervention may 
work better or worse.  
 
A systematic review of 
qualitative evidence on 
barriers and facilitators to 
the implementation of 
task-shifting in midwifery 
services11 
 
A qualitative evidence 
synthesis examined the 
qualitative literature to 
report implementation 
factors associated with 
midwifery task shifting and 
optimization. For this 
complex intervention, the 
question went beyond 
asking if it works, but the 
World Health Organziation 
wanted to know how to 
implement it in the most 
effective way. The 
qualitative evidence 
synthesis elucidated 




Consider modelling if 
appropriate and expertise 
is available 
Various types of modeling 
such as decision analysis 
can be used to fill gaps in 
the evidence base. 
Modelling is time intensive 
but may be appropriate if 
models exist that can be 
adapted to address 
research gaps 
Collaborative Modeling of 
U.S. Breast, Lung, 
Colorectal, and Cervical 
Cancer Screening 
Strategies12 
The systematic review 
addressed the question of 
benefits and harms of 
screening for breast 
cancer. Modeling was 
used to address specific 
remaining gaps about 
combinations of screening 
modalities, frequency and 
start age.  
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Strategy Description Example Example Description 
Incorporate health system 
data into a review 
Local health system data 
can inform decision-
making by augmenting the 
evidence base or by 
informing implementation 
efforts.13 
Endovascular treatment of 
internal carotid artery 
bifurcation aneurysms: a 
single-center experience 
and a systematic review 
and meta-analysis14 
To determine the 
outcomes of endovascular 
treatment of internal 
carotid artery bifurcation 
aneurysms, only 6 small 
surgical series were found 
in the literature (a total of 
only 158 patients). 
Reviewing the electronic 
medical record of a single 
health system (Mayo 
Clinic), identified 37 
additional cases that were 
incorporated into the 
systematic review. This 
addition increased the 
size of the body of 
evidence by 23% and 
provided more granular 
details on patients’ clinical 
characteristics, and thus, 
may further support 
decisionmaking in this 
context, although it may 
not increase strength of 
evidence. 
Acronym: EPC= Evidence-based Practice Center. 
*These strategies may not always be logistically possible during the conduct of the review and may require a separate subsequent 
study.  
Scoping the Topic 
During the scoping stage, when a determination is being made whether a systematic review is 
of interest, of value, and is likely to have sufficient evidence to summarize, it may be possible to 
anticipate and plan for specific findings of insufficient evidence. Early identification and 
engagement of stakeholders can facilitate clear understanding of the decisional context and 
dilemma. This early partnership can also clarify the anticipated volume of the literature, timeline, 
and feasibility of the review. In this case, the specific question and approach can be discussed 
and modified if needed, the possibility of conducting a technical brief can be entertained, and the 
need for some of the approaches to address insufficient evidence can be determined (see below: 
Developing the Protocol, Conducting the Review). 
For complex questions, including questions related to implementation, topic experts could 
offer a good source of information about the quantity and quality of available evidence. Care 
should be taken that all relevant stakeholders are represented and that interview methods are 
adequate to reach thematic saturation. Scoping of a review requires balance and consideration of 
the tradeoffs necessary to keep workloads manageable. See Table 1 for several examples of 
decisional dilemmas and approaches.  
11 
 
Table 2. Review purposes and early decisions about synthesis approach  
Decisional Dilemma Type of Question Decisional Context Approach 




No other known effective 
tests or interventions 
Effectiveness review, 
technical brief if anticipate 
insufficient evidence 
Is a test, strategy, or 
intervention better than 




There are existing 
effective options, but a 
“newer” intervention may 
be more effective. 
Comparative effectiveness 
review with established 
minimally important 
difference 
Is a test, strategy, or 





There is an established 
standard of care, but a 
“newer” intervention is 
expected to be cheaper or 
have fewer harms. 
Comparative effectiveness 
review with established 
minimally important 
difference. A modeling 
study may also be 
considered. 
What is the “best” 
approach among several 
alternative tests, 
strategies, or interventions 
considering tradeoffs for 
different outcomes? 
Net benefit analysis Multiple comparisons, 
each with different levels 




How does a test, strategy, 
or intervention work and 
under what circumstance 




interventions that are 
likely to have 
heterogeneous evidence 
Qualitative evidence 
synthesis or complex 
intervention 
methodologies (such as 
metaregression, finite 




During the scoping stage, it may be possible to anticipate the finding of insufficient evidence. 
In this case, the specific question and approach can be discussed and modified if needed, the 
possibility of conducting a technical brief can be entertained, and the need for some of the 
approaches to address insufficient evidence can be determined (see below: Developing the 
Protocol, Conducting the Review). 
Developing the Protocol  
When developing the protocol, systematic review authors should again consider the most 
appropriate methods and inclusion criteria that are most likely to provide the information to 
answer the question. Authors should determine a priori the outcomes that require strength of 
evidence (SOE) grading (after accounting for stakeholder perspectives and needs, decisional 
context and dilemma), critical and important outcomes, and specific thresholds for determining 
benefit or harm) and consider what other questions and methods to use if there is insufficient 
evidence for an outcome critical for the stakeholder decision making process.  
The stakeholder needs, decisional dilemmas, and context will determine the most appropriate 
outcomes for rating the SOE. As described in the EPC Methods Guide for Effectiveness and 
Comparative Effectiveness Reviews, systematic review authors must also decide a priori what 
outcomes are considered critical for grading.22 Review authors should also consider what 
additional questions and methods may be appropriate if evidence using the proposed criteria 
result in insufficient evidence.23  
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In planning for one or more of these strategies, reviewers should explicitly note if they are 
planning a “best evidence” approach23 which may start with more narrow inclusion criteria, but 
expand to other study designs or populations if evidence is insufficient. In anticipation of 
sufficient evidence, reviewers may decide to restrict to randomized controlled trials and/or to a 
specific target population. However, in the conduct of the study, reviewers may discover that 
flaws in the conduct of the study or overall imprecision or inconsistency lead to insufficient 
evidence. For reviews proposing a “best-evidence approach,” reviewers should plan and describe 
in the protocol what types of other evidence (such as from different study designs, populations, 
comparators, or other types of contextual information) will be considered if initial eligibility 
criteria yields insufficient evidence. Identification of these other types of evidence at the protocol 
stage will allow reviewers to keep track of such types of evidence so that they can modify the 
workflow and improve the efficiency of retrieving studies or information as needed later. This 
approach is consistent with the EPC Methods Guide for Effectiveness and Comparative 
Effectiveness Reviews which recommends including nonrandomized studies if there is 
anticipated insufficient evidence from randomized controlled studies.24    
Conducting the Review 
Ideally, reviewers would anticipate insufficient evidence at the earlier stages of scoping the 
review or developing the protocol and plan for additional approaches of evidence synthesis. 
However, if systematic reviewers find insufficient evidence during the course of review and have 
the time and resources, they may consider these additional strategies based on the reasons for the 
rating or recommended the strategies for next steps or future research. 
Table 3 describes potential reasons for insufficient evidence and corresponding methods that 
may be used to supplement insufficient ratings. Notably, in some instances, the suggested 
approaches may not be logistically feasible during the conduct of the review and may be 
appropriate to recommend for a subsequent study. 
Table 3. Potential strategies to address insufficient evidence  
Reason for Insufficient Evidence Potential Strategies 
No or sparse evidence from 
randomized controlled trials, or 
most studies have high risk of bias 
• For reviews proposing a best-evidence approach, reconsider study 
eligibility of other  study designs 
• Summarize evidence outside the prespecified review parameters 
(indirect evidence). 
• Summarize contextual information (other than evidence on 
benefits/harms) 
• Incorporate health system data into a review 
Indirect outcomes, populations, 
interventions, or settings 
• Summarize evidence outside the prespecified review parameters 
(indirect evidence). 
• Summarize contextual information (other than evidence on 
benefits/harms)   
• Consider modelling if appropriate and expertise is available 
• Incorporate health system data into a review 
Conflicting or heterogeneous 
studies, particularly with complex 
interventions or implementation 
questions 
• Summarize contextual information (other than evidence on 
benefits/harms) 
• Conduct realist review/Qualitative evidence synthesis and/or 
comparative analysis 
• Incorporate health system data into a review 
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Notably, in some instances, these approaches may not be logistically feasible during the conduct 
of the review and may be appropriate to recommend for subsequent study. In other instances 
(e.g., rapid reviews in the context of known uncertainties), reviewers may need to plan for 
several simultaneous strategies. 
Reporting Findings 
Review authors should explicitly state when no studies are available (e.g., “no studies have 
directly evaluated this outcome, or no evidence available”) instead of using the term 
“insufficient.” Review authors can also consider qualifying the term “insufficient” by stating the 
main reason that lead to an insufficient rating (e.g., insufficient because of imprecision). 
Implications for decisionmakers and recommendations for next steps may vary for evidence that 
is insufficient due to conflicting or heterogeneous studies, imprecise estimates of 
effect/association, poor applicability to population of interest, and/or high risk of bias studies. 
Approaches to supplementing evidence or recommendations for next steps may differ. In some 
cases, further exploration of heterogeneity could help to explore if there is an effect in a specific 
populations or settings. Authors should consider different recommendations for future research 
based on the different types of insufficient evidence. 
Discussion 
EPC systematic reviews examine the available evidence on one of the main factors that 
inform decisions – that is, the evidence for benefit or harm. However, decision makers must also 
consider a range of other factors, such as costs, values, preferences, and equity, and the relative 
weight of these factors may vary depending on the topic or the availability of evidence for 
benefit or harm. This report summarizes the findings of a workgroup from the EPC Program that 
sought to understand how systematic reviewers can further support decision making in the face 
of insufficient evidence for benefits or harms. We identified the various ways in which the term 
insufficient evidence has been used, defined, and understood in the literature; and what 
additional strategies can be performed by systematic reviewers to facilitate decisionmaking in the 
context of insufficient evidence. 
We identified several strategies to augment decision making, such as summarizing indirect 
evidence, summarizing contextual and implementation evidence, modeling, and incorporating 
unpublished health system data in the review. One key challenge is that appropriate planning and 
budgeting of a review needs to be done early, alongside conversations with key informants about 
scope, whereas the determination of insufficient evidence may not be made until late in the 
review. As such, reviewers should consider options and strategies early and at each stage of the 
process: during the scoping or the review, protocol development, conducting of the review, and 
when reporting the findings. Even when insufficient evidence is identified later in the review 
process, some of the proposed approaches described to supplement the review may still be 
feasible with appropriate protocol amendments.  
It is important to acknowledge the limitations of the evidence even with the implementation 
of these strategies, as well as our approach to identify them. These strategies do not “fix the 
problem” of insufficient evidence, but rather facilitate decision making in in the context of 
insufficient evidence. For example, adding unpublished health system data to a systematic 
review can improve precision of the estimates and may enhance applicability; however, such 
data are not peer reviewed and can suffer from various types of bias. We may have not included 
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important strategies because our sample was limited to reports in which EPC investigators were 
involved, most of which are conducted for guideline groups or governmental agencies. Our 
evidence about the relative success of these strategies was also indirect and inferred from peer 
and public comments and not directly from end-users.  
The examples, strategies, and recommendations in this document apply to the EPC Program 
and may not apply to other systematic reviewers. Although this project focuses on systematic 
reviews conducted following a traditional timeline, the approach can be applied to rapid reviews 
to address urgent clinical issues. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) pandemic serves as an ongoing example of a public health crisis requiring rapid reviews; 
these reviews may conclude insufficient evidence, yet provide information to support decision 
making.32  
Conclusion  
Systematic reviews commonly examine the evidence on benefits and harms of interventions 
but other factors are required for decisionmaking. When the strength of this evidence warrants 
insufficient rating, information on these factors can enhance the utility of systematic reviews for 
health systems and other stakeholders. We identified five potential strategies including 
broadening eligibility criteria to other study designs, summarizing indirect evidence, 
summarizing contextual and implementation evidence, modelling, and incorporating unpublished 




1.  Berkman ND, Lohr KN, Ansari M, et al. Grading 
the strength of a body of evidence when 
assessing health care interventions for the 
effective health care program of the Agency 
for Healthcare Research and Quality: an 
update.  Methods Guide for Effectiveness 
and Comparative Effectiveness Reviews 
[Internet]. Rockville, MD: Agency for 
Healthcare Research and Quality (US); 
2013. 
2.  Schünemann H, Brożek J, Guyatt G, et al. 
Handbook for grading the quality of 
evidence and the strength of 
recommendations using the GRADE 
approach GRADE Working Group. 2013. 
3.  Alonso-Coello P, Schünemann HJ, Moberg J, et al. 
GRADE Evidence to Decision (EtD) 
frameworks: a systematic and transparent 
approach to making well informed 




4.  Christensen V, Floyd N, Anderson J. “It Would’ve 
Been Nice if They Interpreted the Data a 
Little Bit. It Didn’t Really Say Much, and It 
Didn’t Really Help Us.”: A Qualitative 
Study of VA Health System Evidence 
Needs. Med Care. 2019;57(10 Suppl 
3):S228. doi: 
https://dx.doi.org/10.1097/MLR.000000000
0001171. PMID: 31517792. 
5.  Bridges JF, Berger Z, Austin M, et al. Public 
Reporting of Cost Measures in Health. 
Agency for Healthcare Research and Quality 
Technical Brief. 2015. PMID: 25763451. 
6.  Leas BF, Tipton K, Bryant-Stephens T, et al. 
Characteristics of Existing Asthma Self-
Management Education Packages. Agency 
for Healthcare Research and Quality 
Technical Brief. 2020. PMID: 32369313. 
7.  Snyder D, Sullivan N, Margolis D, et al. Skin 
substitutes for treating chronic wounds. 
Agency for Healthcare Research and Quality 
Technical Brief. 2020. PMID: 32101391. 
8.  O’Neil M, McDonagh M, Hsu F, et al. 
Pharmacologic and Nonpharmacologic 
Treatments for Posttraumatic Stress 
Disorder: Groundwork for a Publicly 
Available Repository of Randomized 
Controlled Trial Data. Agency for 
Healthcare Research and Quality Technical 
Brief. 2019. PMID: 31145565. 
9.  Brasure M, Nelson VA, Scheiner S, et al. 
Treatment for Acute Pain: An Evidence 
Map. Agency for Healthcare Research and 
Quality Technical Brief. 2019. PMID: 
31693321. 
10.  Ibe CA, Wilson LM, Brodine J, et al. Impact of 
Community Health Worker Certification on 
Workforce and Service Delivery for Asthma 
and Other Selected Chronic Diseases. 
Agency for Healthcare Research and Quality 
Technical Brief. 2020. PMID: 32255577. 
11.  Krist AH, Wolff TA, Jonas DE, et al. Update on 
the methods of the US Preventive Services 
Task Force: methods for understanding 
certainty and net benefit when making 
recommendations. Am J Prev Med. 
2018;54(1):S11-S8. doi: 
https://dx.doi.org/10.1016/j.amepre.2017.09.
011. PMID: 29254521. 
12.  Hanquet G, Stefanoff P, Hellenbrand W, et al. 
Strong Public Health Recommendations 
from Weak Evidence? Lessons Learned in 
Developing Guidance on the Public Health 
Management of Meningococcal Disease. 
Biomed Res Int. 2015;2015:569235. doi: 
https://dx.doi.org/10.1155/2015/569235. 
PMID: 26693485. 
13.  Guirguis-Blake JM, Evans CV, Redmond N, et 
al. Screening for peripheral artery disease 
using the Ankle-Brachial Index: updated 
evidence report and systematic review for 
the US preventive services task force. 




14.  Jonas DE, Kahwati LC, Yun JD, et al. Screening 
for atrial fibrillation with 
electrocardiography: evidence report and 
systematic review for the US Preventive 




15.  RTI International–University of North Carolina 
Evidence-based Practice Center. Whole 
Exome Sequencing. Washington State 




16.  Webber E, Thomas R, Lin JS. Implications of 
Multigene Panels for Hereditary Breast 
Cancer Risk Assessment. Not yet published. 
17.  Liem RI, Lanzkron S, D. Coates T, et al. 
American Society of Hematology 2019 
guidelines for sickle cell disease: 
cardiopulmonary and kidney disease. Blood 
Adv. 2019;3(23):3867-97. doi: 
https://dx.doi.org/10.1182/bloodadvances.20
19000916. PMID: 31794601. 
18.  Shekelle PG, Sarkar U, Shojania K, et al. Patient 
safety in ambulatory settings. Agency for 
Healthcare Research and Quality Technical 
Brief. 2016. PMID: 27854399. 
19.  Gaynes B, Brown C, Lux LJ, et al. Relationship 
between use of quality measures and 
improved outcomes in serious mental 
illness. Agency for Healthcare Research and 
Quality Technical Brief. 2015. PMID: 
25654159. 
20.  Adam GP, Di M, Cu-Uvin S, et al. Strategies for 
improving the lives of women aged 40 and 
above living with HIV/AIDS. Agency for 
Healthcare Research and Quality Technical 
Brief. 2016. PMID: 27929614. 
21.  Butler M, Ratner E, McCreedy E, et al. Decision 
aids for advance care planning: an overview 
of the state of the science. Agency for 
Healthcare Research and Quality (US). 
2014;Technical Brief No. 14-EHC039-EF. 
PMID: 25069709. 
22.  Berkman ND, Lohr KN, Ansari M, et al. Grading 
the strength of a body of evidence when 
assessing health care interventions for the 
effective health care program of the Agency 
for Healthcare Research and Quality: an 
update.  Methods Guide for Effectiveness 
and Comparative Effectiveness Reviews 
[Internet]. Agency for Healthcare Research 
and Quality (US); 2013. 
23.  Treadwell JR, Singh S, Talati R, et al. A 
framework for" best evidence" approaches 
in systematic reviews. Agency for 
Healthcare Research and Quality. 2011. 
PMID: 21834173. 
24.  Norris S, Atkins D, Bruening W, et al. Selecting 
observational studies for comparing medical 
interventions.  Methods guide for 
effectiveness and comparative effectiveness 
reviews [Internet]. Agency for Healthcare 
Research and Quality (US); 2010. 
25.  Brandow AM, Carroll CP, Creary S, et al. 
American Society of Hematology 2020 
guidelines for sickle cell disease: 
management of acute and chronic pain. 
Blood Adv. 2020;4(12):2656-701. doi: 
https://dx.doi.org/10.1182/bloodadvances.20
20001851. PMID: 32559294. 
26.  Wang Z, Whiteside SP, Sim L, et al. Comparative 
effectiveness and safety of cognitive 
behavioral therapy and pharmacotherapy for 
childhood anxiety disorders: a systematic 
review and meta-analysis. JAMA Pediatr. 
2017;171(11):1049-56. doi: 
https://dx.doi.org/10.1001/jamapediatrics.20
17.3036. PMID: 28859190. 
27.  Morrow AS, Whiteside SP, Sim LA, et al. 
Developing tools to enhance the use of 
systematic reviews for clinical care in health 
systems. BMJ Evid Based Med. 
2018;23(6):206-9. doi: 
https://dx.doi.org/10.1136/bmjebm-2018-
110995. PMID: 30194075. 
28.  Colvin CJ, de Heer J, Winterton L, et al. A 
systematic review of qualitative evidence on 
barriers and facilitators to the 
implementation of task-shifting in 
midwifery services. Midwifery. 
2013;29(10):1211-21. doi: 
https://dx.doi.org/10.1016/j.midw.2013.05.0
01. PMID: 23769757. 
17 
29.  Writing Committee of the Breast Cancer 
Working Group, Cancer Intervention and 
Surveillance Modeling Network (CISNET), 
Breast Cancer Surveillance Consortium 
(BCSC). Collaborative Modeling of U.S. 
Breast Cancer Screening Strategies. Agency 
for Healthcare Research and Quality (US). 
2015;Report No. 14-05201-EF-4.  
30.  Lin JS, Murad MH, Leas B, et al. Integrating 
Health System Data With Systematic 
Reviews: A Framework for When and How 
Unpublished Health System Data Can Be 
Used With Systematic Reviews To Support 
Health System Decision Making. Agency 
for Healthcare Research and Quality (US). 




31.  Morales-Valero S, Brinjikji W, Murad MH, et al. 
Endovascular treatment of internal carotid 
artery bifurcation aneurysms: a single-center 
experience and a systematic review and 




32.  Chou R, Dana T, Jungbauer R, et al. Masks for 
prevention of respiratory virus infections, 
including SARS-CoV-2, in health care and 
community settings: a living rapid review. 




Abbreviations and Acronyms  
 
AHRQ  Agency for Healthcare Research and Quality  
EPC  Evidence-based Practice Center  
GRADE Grading of Recommendations Assessment, Development and Evaluation 
KI   Key Informant  
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2  
SoE  Strength of evidence 
SRC  Scientific Resource Center 






Appendix A. Search Strategies  
Ovid MEDLINE(R) ALL 1946 to September 25, 2019 
Date searched: September 27, 2019 
Searched by: Robin Paynter, MLIS 
# Searches Results 
1 ((absence or equivocal or incomplete or insufficient or minimal or missing or "not 
enough" or uncertain*) adj2 (effectiveness or evidence or research)).ti. 
894 
2 ((absence or equivocal or incomplete or insufficient or minimal or missing or 
uncertain*) adj2 (effectiveness or evidence or research)).ti,ab. or "Evidence to 
decision".kf. or ((utili?ation or weak) adj2 evidence).ti. 
16096 
3 Decision Making/ or Delivery of Health Care/ or Health Policy/ or Health Services 
Research/ or Policy Making/ or Uncertainty/ 
282423 
4 (((evidence-based or evidence-informed) adj2 (policy* or policies)) or decision* or 
((health* or hospital) adj2 (system or systems)) or policies or policy*).ti,kf. 
164219 
5 or/3-4 385350 
6 and/2,5 720 
7 or/1,6 1538 
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Appendix C. Review of Systematic Reviews 
Table C-1. List of reports included in the review of systematic reviews 
Report Title 
(43 articles) 
Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Screening to Prevent 
Osteoporotic Fractures: 
An Evidence Review for 
the U.S. Preventive 
Services Task Force1 
What Are the Harms 
Associated with 
Pharmacotherapy? 
United States Preventive 
Services Task Force 
(USPSTF) 
Whether or not to recommend 
screening to prevent osteoporotic 
fractures. The screening decision 
requires understanding whether 
screening is accurate in identifying 
those at risk, and then in 
identifying whether treatment of 
those at risk is safe and effective 
compared to no treatment.  
No eligible evidence 
Speech and Language 
Delay and Disorders in 
Children Age 5 and 
Younger: Screening2 
Do Interventions for 
Speech and Language 
Delays or Disorders 
Improve Speech and 
Language Outcomes? 
USPSTF Whether to recommend screening 
of speech and language disorders. 
To assess whether screening for 
speech and language delays or 
disorders in young children, 
required determining whether 
screening tests were accurate and 
whether treatments for those 
identified with disorders are 
beneficial and without any harm. 
  
Inadequate evidence due to 
inconsistent findings on 
outcomes, studies conducted 
in high risk populations, 
children's speech and 
language delays had not 
been detected by screening 




Risk 1 With Resting or 
Exercise 
Electrocardiography:  
Evidence Report and 
Systematic Review for 
the US Preventive 
Services Task Force3 
Does the addition of 
screening with resting or 
exercise ECG to traditional 
CVD risk factor 
assessment accurately 
reclassify persons into 
different risk groups (eg, 
high-, intermediate-, and 
low-risk groups) or improve 
measures of calibration 
and discrimination? 
USPSTF   Recommend additional screening 
with ECG or EGC exercise stress 
For calibration - 4 studies but 
all have different metrics for 
calibration. For NRI - only 
one study 
Screening for Atrial 
Fibrillation With 
Electrocardiography: An 
Evidence Review for the 
U.S. Preventive Services 
Task Force4 
KQ3. What Are the Harms 
of Screening for AF With 


















3 KQs had insufficient 
(GRADE equivalent of 
VERY LOW): 
1. What is the clinical utility 
of WES (i.e., changes to 
medications, further 
diagnostic testing, other 
treatment/management)? 
2. What is the impact on 
health outcomes from use 
of WES? 
3. What is the cost-
effectiveness of WES 





Committee   
Whether to cover WES as included 
benefit for state-purchased health 
care (i.e., Medicaid, Dept of 
Corrections, Workers Comp, and 
State Employee's Health Plan) in 
the absence of sufficient evidence. 
Bodies of evidence for the 
KQ noted here had serious 
study limitations (risk of bias), 
serious inconsistency, and 
serious imprecision; this 
resulted in VERY LOW 
GRADE certainty ratings 
(equivalent to AHRQ 
Insufficient). 
Screening for Unhealthy 
Drug Use in Primary 




Review for the US 
Preventive Services Task 
Force6 
KQ1: Does primary care 
screening for drug use in 
adolescents and adults 
reduce drug use or 
improve other risky 
behaviors or reduce 
morbidity or mortality and 
improve other health, 
social, or legal outcomes? 
KQ3: What are the harms 
of primary care screening 
for drug use in adolescents 
and adults?" 
USPSTF Whether to recommend drug 
screening or not  
No eligible evidence 
Implications of Multigene 
Panels for Hereditary 
Breast Cancer (HBOC) 
Risk Assessment7 
What is the accuracy of 
familial risk assessment 
tools for hereditary breast 
and ovarian cancer when 
performed by a non-
specialist in genetics in a 
clinical setting? Have any 
of these risk assessment 
tools been validated 
against multigene panels? 
What are the optimal ages 
and intervals for risk 
assessment? 




recommendations (BRCA testing) 
and clinical care (multigene panel 
testings)  
No eligible studies compared 
with multigene panel testing 
(all were compared with 







Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Screening for Peripheral 
Artery Disease Using the 
Ankle-Brachial Index: An 
Updated Systematic 
Review for the U.S. 
Preventive Services Task 
Force8 
KQ2 What is the diagnostic 
accuracy of the ABI as a 
screening test for PAD in 
generally asymptomatic 
adults? 
USPSTF  1 older fair-quality study in a 
restricted population shows poor 
accuracy. How generalizable is 
this study to other ages and in the 
contemporary US? 
1 small study of fair quality 
restricted to a population of 
older adults (age 70) in 
Sweden showing very low 
sensitivity (95% CI, 7% to 
34%) 
Periodic Screening with 
the Pelvic Examination9  
KQ1: What is the direct 
evidence for the 
effectiveness of screening 





morbidity and mortality, 
improving quality of life 
KQ2: What are the test 
performance 
characteristics of the pelvic 
examination (i.e., 
sensitivity, specificity, 
positive and negative 
predictive values) in 
screening for 
gynecological cancers and 
other gynecological 
conditions? 
KQ3: What are the 
adverse effects of 
screening with the pelvic 
examination? 
USPSTF Very few studies in appropriate 
asymptomatic populations seen in 
primary care. Limited evidence for 
evaluating detection rates for few 
conditions. No direct evidence on 
effectiveness, little evidence on 
harms applicable to primary care 
populations . 
Insufficient evidence for 
determining test performance 
of screening test - few 
studies, not very applicable 
evidence. No studies with 
direct evidence and few 
studies with limited 







Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Screening for Pancreatic 
Cancer: Updated 
Evidence Report and 
Systematic Review for 
the US Preventive 
Services Task Force10 
KQ1. Does screening for 
pancreatic 
adenocarcinoma improve 
cancer morbidity or 
mortality or all-cause 
mortality?; KQ4. Does 
treatment of screen-
detected or asymptomatic 
pancreatic 
adenocarcinoma improve 
cancer mortality, all-cause 
mortality, or quality of life? 
USPSTF Whether or not to recommend 
screening for pancreatic cancer in 
asymptomatic people   
No eligible evidence 
Behavioral Counseling 
for Skin Cancer 
Prevention: A 
Systematic Evidence 
Review for the U.S. 
Preventive Services Task 
Force11 
KQ4. What is the 
association between skin 
self-examination and skin 
cancer outcomes 
(melanoma, squamous 
cell, or basal cell 
carcinoma incidence, 
morbidity, or mortality)?; 
KQ5. What are the harms 
of skin self-examination? 
USPSTF Whether or not to recommend 
behavioral counseling for skin 
cancer prevention in asymptomatic 
people  
No eligible evidence 
Screening for 
Adolescent Idiopathic 
Scoliosis: A Systematic 
Evidence Review for the 
U.S. Preventive Services 
Task Force12 
KQ1. Does screening for 
adolescent idiopathic 
scoliosis improve: a) health 
outcomes, and b) the 
degree of abnormal spinal 
curvature in childhood or 
adulthood?; KQ5. What 
are the harms of screening 
for adolescent idiopathic 
scoliosis? 
USPSTF  Whether or not to recommend 
screening for idiopathic scoliosis in 
adolescents 
No eligible evidence 
Comparative 
effectiveness and safety 




disorders: a systematic 
review and meta-
analysis13 
Are SNRIs drug class 
effective in reducing 
anxiety symptoms as 
reported by the patient? 
None, the question was 
nominated by a researcher 
  
Whether to use medications in 
children with anxiety, particularly 
younger children 
Severe imprecision (wide 







Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
The Clinical Utility of 
Fractional Exhaled Nitric 
Oxide (FeNO) in Asthma 
Management14 
In children ages 0-4 years 
with recurrent wheezing, 
can FeNO predict the 
future development of 
asthma? 
National Heart, Lung, and 
Blood Institute (NHLBI)  
Should we do the test on very 
young children who present with 
wheezing to predict whether they 
will develop asthma after the age 
of 5 years? 
Contradictory results of 
studies that were 
summarized narratively 




Therapies in Adult 
Patients with 
Exacerbation of COPD15 
In adult patients with acute 
exacerbation of COPD, 
what are the benefits and 
harms of systemic 
corticosteroids and 
antibiotics compared with 
placebo or standard care? 
American Academy of Family 
Physicians   
Using antibiotics for acute COPD 
exacerbations  
Severe imprecision (wide 
CIs) and risk of bias 
American Society of 
Hematology 2019 




Should screening for 
abnormal pulmonary 
function vs no screening 
be performed for 
asymptomatic patients with 
SCD? 
American Society of 
Hematology   
Whether to recommend routine 
screening with PFTs in patients 
with sickle cell disease 
Observational studies with 





Women: An Endocrine 
Society*Clinical Practice 
Guideline17 
In postmenopausal women 
at high risk of fracture with 
osteoporosis, should 
calcitonin be used to 
reduce the risk of 
fractures? 
Endocrine Society  Using a likely less effective 
medicine  
Imprecise estimates for hip 
and nonvertebral fracture 
outcomes, high risk of bias in 
trials of all three outcomes 




Guideline for the 
Treatment of Psoriatic 
Arthritis18  
In adult patients with active 
Psoriatic Arthritis, what are 
the benefits and harms of 
exercise compared to no 
exercise? 
American College of 
Rheumatology   
Whether to recommend exercise in 
patients with psoriatic arthritis 
No eligible evidence 
Testing for Clostridium 
Difficile in Oncology 
Patients19 
In inpatient oncology adult 
patients, which tests for C. 
diff (ELISA and/or PCR) 
should be used for 
diagnosis? 
University of Pennsylvania 
Health System executives 
and clinicians  
Inability to standardize accurate 
diagnosis of C diff in oncology 
patients, in an effort to reduce 
false positive tests and over-
treatment  







Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Oral antibiotics for 
secondary prophylaxis 
following two-stage 
revision surgery for 
prosthetic joint 
infection20 
What is the effectiveness 
and safety of oral antibiotic 
prophylaxis following 
completion of two-stage 
revision surgery performed 
following a first episode of 
prosthetic joint infection? 
University of Pennsylvania 
Health System executives 
and clinicians  
Whether or not to recommend 
antibiotic prophylaxis after 
completion of two stage-revision 
surgery, for those with a history of 
prosthetic joint infection  
Strength of evidence base 
limited by small size, 
heterogeneity, and quality of 
studies.  Evidence does not 
indicate an optimal treatment 
regimen or duration of 
therapy, or identify whether 
the effectiveness of treatment 
varies by patient 
characteristics. Also low 
strength evidence indicating 
that oral antibiotic therapy 
does not result in serious 
AEs (not systematically 
addressed across studies) 
Effectiveness of Indoor 
Allergen Reduction in 
Management of Asthma21 
Among individuals with 
asthma, what is the 
effectiveness of 
interventions to reduce or 
remove exposures to 
indoor inhalant allergens 
on asthma control, 
exacerbations, quality of 
life, and other relevant 
outcomes? 
NHLBI guideline panel 
  
Whether to recommend air 
purification for asthma patients 
Substantial inconsistency and 
imprecision. 1 RCT (low risk 
of bias) showed no 
differences in asthma control 
scores. 1 RCT (high risk of 
bias) showed improvement in 
combined asthma outcomes. 
1 RCT (low risk of bias) did 
not report differences in 
asthma scores. 
Effectiveness and Safety 
of Bronchial 
Thermoplasty in 
Management of Asthma22 
What are the benefits and 
harms of using BT in 
addition to standard 
treatment for the treatment 
of adult (≥18 years) 
patients with asthma? 
NHLBI guideline panel 
  
Whether to recommend bronchial 
thermoplasty  
Study limitations; inability to 
assess consistency given 
only 1 study; unknown 
imprecision given only 1 
study; no differences 
observed between 
intervention and control 
groups, so unable to evaluate 











Implications for Energy 
Balance in the United 
States and Mexico: A 
Systematic Review of the 
Evidence and Meta-
Analysis23 
What are the effects of 
obesity prevention policies 
on energy consumed and 
expended? 
Abstract public health policy 
maker   
What policies can be implemented 
to reduce obesity? 
Few studies reported 
outcomes of interest (energy 
consumption and 
expenditure), and ever fewer 
focused on children 
A Systematic Review in 
Support of the National 
Consensus Project 
Clinical Practice 
Guidelines for Quality 
Palliative Care, Fourth 
Edition24 
(KQ2) What is the impact 
of palliative care 
interventions on physical 
symptom screening, 
assessment, and 
management of patients?    
(KQ4) Does an 
assessment of 
environmental or social 
needs as part of a 
comprehensive palliative 
assessment improve 
needs identification and 
access to relevant 
services? 
(KQ7a) What is the effect 
of grief and bereavement 
programs on 
family/caregiver 
outcomes?   
NR "Inform National Consensus 
Project (NCP) Clinical Practice 
Guidelines for Quality 
Palliative Care" 
NR 
Effects of medication 
assisted treatment (MAT) 
for opioid use disorder 
on functional outcomes: 
A systematic review25 




naloxone, methadone, or 
naltrexone) for OUD on 
functional outcomes 
compared to wait-list, 
placebo, treatment without 
medication, any other 
comparator, or each other 
(e.g., buprenorphine vs 
naltrexone)? 











Disorder: A Systematic 
Review26 
What are the effects of 




health-related quality of 
life, functional status, and 
adverse events compared 
with treatment as usual, 
waitlists, no treatment, or 
other active treatments, in 
adults with posttraumatic 
stress disorder? 
VA National Center for 
Patient Safety .  
 
Meditation approach, intervention 
intensity, and study quality varied 
considerably 
"meditation improved PTSD 
symptoms and depression 
symptoms. However, these 
positive findings are based 
on low to moderate ratings of 
quality of evidence, and only 
a small number of studies 
were available in each 
meditation category  
 
Given the lack of 
monotherapy studies, it was 
not possible to determine 
differential effects of 
offering meditation as 
adjunctive or monotherapy." 
Wrong-site surgery, 
retained surgical items, 
and surgical fires: a 
systematic review of 
surgical never events27 
What is the effectiveness 
of the individually identified 
interventions for the 
prevention of wrong site 
surgery, retained surgical 
items, and surgical fires? 
Veterans Affairs (VA) 
managers and policymakers 
 




"improve the health and healthcare 
of Veterans 
 
Develop a standardized, single, 
strong recommendation to VA 
facilities in the effort to eliminate 
wrong site surgery, retained 
surgical items, and surgical fires."
  
Despite promising 
approaches and global 
Universal Protocol 
evaluations, empirical 
evidence for interventions is 
limited. 
Adverse Effects of 
Pharmacologic 
Treatments of Major 
Depression in Older 
Adults28 
To assess adverse effects 
of pharmacologic 
antidepressants for 
treatment of major 
depressive disorder (MDD) 
in adults 65 years of age or 
older. 
(?) Data used to create 
report was all done by 
investigators at EPC  
Are the adverse events severe 
enough, persistent enough, or 
consistent enough to warrant 
reconsideration of use in patients 
65+.  
risk of bias, imprecisions, 
suspected selective reporting 
bias, and withdrawal of 
patients who had an adverse 








Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Association of Inhaled 
Corticosteroids and 
Long-Acting β-Agonists 
as Controller and Quick 
Relief Therapy with 
Exacerbations and 
Symptom Control in 
Persistent Asthma29 
What is the efficacy 
associated with using 
inhaled corticosteroids and 
long-acting β-agonists 
(LABAs) together as both 
the controller and the quick 
relief therapy termed single 
maintenance and reliever 
therapy (SMART) in 
patients with persistent 
asthma? 
(?) Data used to create 
report was all done by 
investigators at EPC 
  
 .   
Whether the combination of LABAs 
+ ICS should be used for both 
quick relief and as a control 
risk of bias, inconsistency, 
lack of directness, lack of 




Analgesics to Reduce 
Acute Pain in the 
Prehospital Setting30 
What is the effectiveness 
and harms of opioid and 
nonopioid analgesics for 
the treatment of moderate 
to severe acute pain in the 
prehospital setting? 
(?) Data used to create 
report was all done by 
investigators at EPC 
What agent is the best to use in 
emergency settings to pain 
"Indirect evidence and not 
many reports of adverse 
events for treatments for 
ketamine, NSAID, and 
acetaminophen comparison. 
in at 15 minutes. 
 







surgery: a systematic 
review31 
What are the benefits and 
harms of prolonged versus 
standard-duration 
thromboprophylaxis after 
major orthopedic surgery 
in adults? 
(?) Data used to create 
report was all done by 
investigators at EPC  
Should standard or prolonged-
duration VTE prophylaxis be used 
in knee replacement or hip fracture 
surgery.  
Most trials had few events, 
not much evidence for knee 











intervention of native 
vessels32 
Compare effectiveness 
and safety of adjunctive 
devices to remove thrombi 
or protect against STEMI 
in patients undergoing PCI 
of native vessels. 
(?) Data used to create 
report was all done by 
investigators at EPC  
Are medical devices  safe and 
effective long-term for patients with 
STEMI  
Few trials followed patients 








Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Antipsychotics for the 
Prevention and 
Treatment of Delirium33 
Treatment of delirium AGS  Updating BEERS criteria  inconsistent; indirect; 
imprecise; assessed delirium 
severity using different 
instruments in different 
patient populations with 
inconsistent results 
Use of Cardiac 
Resynchronization 
Therapy34 
Use of specific CRT CMS   Coverage decisions No direct comparison 
reported (reported 
comparison to optimal 
medical therapy) 
Renal Denervation in the 
Medicare Population35 
What is the evidence for 
renal denervation 
effectiveness in other 
conditions such as heart 
failure and arrhythmias? 
CMS   Coverage decisions This was a technical brief, 
and we did not perform the 
usual grading of strength of 
evidence. For this KQ, we 
concluded that "data were 
very limited on the efficacy 
for conditions other than 
resistant hypertension." 
Under the usual grading 
scheme, we would have 
called this insufficient 
evidence because there were 
no large RCTs and the 
available studies were very 
small with a high risk of bias 
and little consistency in how 
outcomes were reported. 
Management of Renal 
Masses and Localized 
Renal Cancer36 
Efficacy and comparative 
efficacy of different 
interventions for the 
management of a renal 
mass suspicious for 
localized renal cell 
carcinoma 
American Urological 
Association   
Used in updating their guidelines 
on management options 
Evidence was insufficient on 
a number of the comparisons 
of interest. For some 
comparisons and some 
outcomes, there were no 
studies. For other 
comparisons and outcomes, 
there were a few studies, but 
the studies had high risk of 
bias and important 














with placebo or no active 
treatment for substance 
use disorders and 
problematic substance use 
in adolescents to achieve 
abstinence, reduce 
quantity and frequency of 
use, improve functional 
outcomes, and reduce 
substance-related harms? 
AACP Whether or not to recommend MI 
with the goal of attaining 
abstinence from alcohol, cannabis,  
 
Whether or not to recommend 
education with the goal of 
decreasing substance related 
problems. 
 
Which nonbrief intervention or 
combination of behavioral 
interventions are superior among 
active interventions. 
Is buprenorphine more effective 
than clonidine to reduce opioid use 
or achieve abstinence. 
 
Does memantadine in addition to 
buprenorphine lead to higher rates 
of abstinence and/or less use. 
 
Does cyanamide compared to 
placebo reduce alcohol use or 
increase abstinence? 
 
Should disulfiram or naltrexone be 
recommended to reduce alcohol 
use or increase abstinence in 
adolescents with alcohol use 
disorder? 
 
Which treatment (combined with 
Educ), Naltrexone or Disulfiram 
should be recommended to reduce 
alcohol use or increase 
abstinence? 
 
Should treatment with N-
acetylcysteine be recommended 
for cannabis use disorder, in 
addition to case management? 
 
Should treatment with topiramate 
be recommended for cannabis use 




consistency of sparse 
evidence network 
  










Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
disorder, in addition to motivational 
interviewing? 
Nonsurgical Treatments 
for Urinary Incontinence 
in Women: A Systematic 
Review Update38 
Key Questions 1-4: What 
are the benefits and harms 
of nonpharmacological and 
pharmacological (and 
combination) treatments of 
UI in women, and how do 
they compare with each 
other? 
PCORI, Public  
 
Effective and most effective 
interventions for women to 
manage stress and urge UI 
1. Combination of indirect 
evidence only (indirect 
comparison in NMA) and 
imprecise estimate. 
2. Lack of evidence (for 
subgroup analyses of 
interest) 
3. Combination of 
inconsistent (discordant) and 
imprecise ratings in EP. 




Component Effects by 
Subgroups, and Long-
Term Outcomes39 
KQ 4. In adults who use a 
lower limb prosthesis, how 
do ambulatory, functional, 
and patient-centered 
outcomes with different 
prosthetic components 
vary based on study 
participant characteristics? 
KQ 6. What is the level of 
patient satisfaction with the 
process of accessing an 
LLP (including experiences 
with both providers and 
payers)? 
KQ 7. At 6 months, 1 year, 
and 5 years after receipt of 
an LLP, (accounting for 
intervening mortality, 
subsequent surgeries, or 
injuries) what percentage 
of individuals… (various 
outcomes)? 
CMS, prosthesis researchers 
and clinicians  
 
Choice of the appropriate lower 
limb prosthesis for individual 
amputees  
KQ 4. Single study (also high 
RoB, single study, indirect--
highly limited applicability). 
KQ 5. Lack of evidence/no 
studies 
KQ 7. Single study (also 
indirect--limited applicability 
to primary population of 
interest [CMS]) 
KQ 7. Inconsistent findings 
across studies (differences in 








Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
WHO guidelines for the 
pharmacological and 
radiotherapeutic 
management of cancer 
pain in adults and 
adolescents40 
1. Choice of 
pharmacotherapy for 
analgesia (for cancer pain) 
2. Effect and harms of 
opioid switching/rotation 
3. Comparison of opioid 
formulations 
4. Comparisons regimens 
for ceasing opioids 
5. Comparative effects and 





6. Radiotherapy for 
(painful) bone metastases 
WHO for international CPG
  
Safe and effective treatment of 
cancer pain with minimization of 
AEs  
Marching across GRADE 
table to achieve Very Low 
KDIGO Clinical Practice 
Guidelines for the 
Prevention, Diagnosis, 
Evaluation, and 
Treatment of Hepatitis C 
in Chronic Kidney 
Disease41 
Multiple KQs to cover 12 
Guideline topics. Testing 
for HCV, Determination of 
whether to treat HCV, 
Choice of HCV treatment, 
Preventing HCV 
transmission, Issues 
pertaining to kidney 
transplantation, Diagnosis 
of HCV-related kidney 
diseases, Treatment of 
HCV-related kidney 
diseases 
KDIGO CPG development 
workgroup, patients, 
clinicians   
Best and appropriate management 
of patients with CKD and HCV 
infection (or risk of exposure) 
Marching across GRADE 












Children and Young 
Adults: Systematic 
Review Update42 
KQ 1: What are the 
benefits, in terms of 
intermediate and 
effectiveness outcomes, of 
first and second generation 
antipsychotics—at the 
level of individual 
antipsychotics and across 
each class—in 
comparisons with placebo, 
different doses of the same 
antipsychotic, or different 
antipsychotics in children 
and young adults (≤24 
years)? 
KQ 2: Across all conditions 
of interest, what are the 
harms of first- and second-
generation 
antipsychotics—at the 
level of individual 
antipsychotics and across 
each class—in 
comparisons with placebo, 
different doses of the same 
antipsychotic, or different 
antipsychotics in children 
and young adults (≤24 
years)? 
American Academy of Child 
and Adolescent Psychiatry 
Best and appropriate management 
of patients with CKD and HCV 
infection (or risk of exposure) 
 
SGAs for treatment resistant 
eating disorders 
 
Effects with long-term treatment for 
bipolar disorder 
 
What SGA may have lower major 
AEs over short- or long-term 
treatment 
Marching across GRADE 
table to achieve Very Low 
Failure to provide data by 
group (for determining 
consistency and precision) 
and the small sample sizes 
(imprecision) were the main 
reasons 
 
ROB, inconsistency and 
imprecision 
 
Data for rare AEs was mostly 
from single studies having 
small sample sizes and 
moderate or higher ROB, 








Key Question End-user Decisional Dilemma Reason for Insufficient 
Evidence Rating 
Behavioral Programs for 
Type 1 Diabetes Mellitus: 
A Systematic Review 
and Meta-analysis43 
KQ 1: For patients with 
T1DM, are behavioral 
programs 
implemented in a 
community health setting 
effective compared with 
usual 
or standard care, or active 
comparators in— 
a. Improving behavioral, 
clinical, and health 
outcomes? 
b. Improving diabetes-
related health care 
utilization? 
c. Achieving program 
acceptability as measured 
by participant attrition 
rates? 
No identified end user for 
this one; public nomination 
  
Whether and what type of program 
to implement 
QoL: ROB, inconsistency (or 
lack of consistency due to 
one study), and imprecision. 
No trials reported on micro- 
and macrovascular 
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